Stockscreener 앱 받기
38.80
0.94%
0.36
시간 외 거래:
38.40
-0.40
-1.03%
전일 마감가:
$38.44
열려 있는:
$38.01
하루 거래량:
1.27M
Relative Volume:
0.84
시가총액:
$6.12B
수익:
$813.46M
순이익/손실:
$-365.74M
주가수익비율:
-13.52
EPS:
-2.87
순현금흐름:
$-375.18M
1주 성능:
-2.29%
1개월 성능:
+2.35%
6개월 성능:
-7.55%
1년 성능:
-17.78%
1일 변동 폭
$37.53
$39.20
1주일 범위
$37.53
$40.12
52주 변동 폭
$35.95
$54.44
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals (NASDAQ:IONS) Upgraded to Hold at StockNews.com - MarketBeat
FDA Sets Goal Date for Donidalorsen in HAE - Managed Healthcare Executive
Acromegaly Pipeline 2024: Clinical Trials Assessment, FDA - openPR
FDA accepts donidalorsen NDA for prophylactic hereditary angioedema - Contemporary Pediatrics
FDA accepts Ionis NDA for donidalorsen - The Pharma Letter
Ionis' donidalorsen awaits FDA decision for HAE treatment - Investing.com
Ionis announces FDA acceptance of New Drug Application for donidalorsen for prophylactic treatment of HAE - PR Newswire
Countdown to Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Shareholders in Ionis Pharmaceuticals (NASDAQ:IONS) have lost 32%, as stock drops 4.0% this past week - Simply Wall St
abrdn plc Has $12.06 Million Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Zilganersen granted U.S. FDA Fast Track designation for people l - GuruFocus.com
Ionis to hold third quarter 2024 financial results webcast - GuruFocus.com
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Short Interest Down 6.3% in October - MarketBeat
International Assets Investment Management LLC Buys 319,065 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - MSN
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
Ionis Pharmaceuticals (IONS) to Release Quarterly Earnings on Wednesday - MarketBeat
Antisense Oligonucleotides Market Is Booming Worldwide - openPR
HEART FAILURE (HF) WITH REDUCED EJECTION FRACTION (HFREF) - openPR
AbbVie to acquire a J&J-backed brain drugmaker for $1.4B - BioPharma Dive
Multiple System Atrophy Market Growth to Accelerate in Forecast - openPR
IONS' Rare Neurology Disorder Candidate Gets FDA's Fast Track Tag - MSN
Ionis Pharmaceuticals (NASDAQ:IONS) Rating Lowered to Sell at StockNews.com - MarketBeat
Ionis: Expect More Of The Same In Terms Of Earnings, Despite Regulatory Successes (NASDAQ:IONS) - Seeking Alpha
Analysts Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Price Target at $60.28 - MarketBeat
Certain warrants of Ionis Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 25-OCT-2024. - Marketscreener.com
Ionis Pharmaceuticals: Catalysts Due In 2025/2026 Are Extremely Compelling - Seeking Alpha
Ionis Pharmaceuticals' (NASDAQ:IONS) investors will be pleased with their 30% return over the last three years - Yahoo Finance
EU CHMP recommends AstraZeneca and Ionis’ Wainzua for ATTRv-PN - Yahoo! Voices
AZ, Ionis get CHMP backing for ATTR polyneuropathy drug - pharmaphorum
Spinocerebellar Ataxias Pipeline Review 2024: Clinical Trials Update and Key Companies Involved by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc - Barchart
RNA-based Therapeutics Market Latest Trends Analysis Report 2024 - InsightAce Analytic
WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis - Quantisnow
Ionis Pharmaceuticals EVP Eric Swayze sells $2,030 in stock - Investing.com
Ionis Pharmaceuticals EVP Eric Swayze sells $2,030 in stock By Investing.com - Investing.com UK
EVP Research Swayze Eric converted options into 125 shares and sold $2,031 worth of shares (53 units at $38.31) (SEC Form 4) - Quantisnow
Spinal Muscular Atrophy Pipeline Insights 2024: Therapies, - openPR
Q3 2024 Earnings Forecast for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Issued By Leerink Partnrs - MarketBeat
Ionis Pharmaceuticals Enters Oversold Territory (IONS) - Nasdaq
Amyotrophic Lateral Sclerosis Market 2034 | Mitsubishi Tanabe - openPR
Acromegaly Pipeline Insights and Analysis 2024: FDA Approvals , and Treatment Outlook | Pfizer Inc, Novartis AG, Validus Pharma, Ipsen, Chiasma, Inc, Crinetics Pharma, Ionis Pharma - Barchart
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire Inc.
Global Antisense & RNAi Therapeutics Market Growth in Future - openPR
Familial Chylomicronemia Syndrome Therapeutics Market to Expand with Significant CAGR by 2034 |Akcea Therapeutics, Ionis – IndiaPolitics.com - IndiaPolitics.com
Sanctuary Advisors LLC Takes Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Where are the Opportunities in (IONS) - Stock Traders Daily
Why Ionis Pharmaceuticals Inc Tanked and Alnylam Pharmaceuticals, Inc. Is Soaring Today - The Pantagraph
Millennium Management LLC Has $6.11 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Transthyretin Amyloid Cardiomyopathy Market Emerging - openPR
Dimensional Fund Advisors LP Has $4.23 Million Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS): Among The Stocks With Biggest Upside Potential According to Hedge Funds - Insider Monkey
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ionis Pharmaceuticals Inc 주식 (IONS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Swayze Eric | EVP Research |
Oct 16 '24 |
Sale |
38.31 |
53 |
2,031 |
157 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 29 '24 |
Sale |
49.63 |
331 |
16,428 |
84,823 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 28 '24 |
Sale |
49.16 |
320 |
15,731 |
85,154 |
| Geary Richard S | EVP, Chief Development Officer |
Aug 05 '24 |
Sale |
48.00 |
2,430 |
116,640 |
85,508 |
2.02%
0.47%
자본화:
|
볼륨(24시간):